Press release
Familial Amyloid Polyneuropathy (FAP) Market to Reach USD 5.48 Billion by 2034
Familial Amyloid Polyneuropathy
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72015
Market Summary
The Familial Amyloid Polyneuropathy Market is expanding rapidly as breakthroughs in RNA-based therapeutics transform management of this rare, progressive, and life-threatening genetic disorder. FAP is caused by mutations in the transthyretin (TTR) gene, leading to misfolded protein deposition in peripheral nerves and vital organs, resulting in progressive polyneuropathy and autonomic dysfunction.
Major advancements in TTR gene-silencing treatments-including RNA interference (RNAi) therapies like patisiran and antisense oligonucleotides (ASOs) like inotersen-have significantly improved outcomes. Additionally, tafamidis, a TTR stabilizer, continues to be widely adopted for early-stage disease. Ongoing research into CRISPR-based genome editing, next-generation RNA platforms, and combination approaches is elevating treatment potential.
Diagnostic improvements using genetic testing, nerve conduction studies, biopsy confirmation, MRI neurography, and emerging biomarkers enable earlier detection, expanding the treatable patient pool.
North America and Europe lead the market due to strong adoption of advanced therapies, while Asia-Pacific is the fastest-growing region owing to larger genetic clusters and improving access to specialty care.
Key Takeaways
• 2024 Market Size: USD 2.93 Billion
• 2034 Forecast: USD 5.48 Billion
• CAGR: 6.5% (2025-2034)**
• RNAi therapies and ASOs dominate the current treatment landscape
• Genetic screening expanding early diagnosis
• Asia-Pacific expected to grow fastest due to rising awareness and improved testing
Market Drivers
• Breakthroughs in RNA interference and antisense therapy
• Expanding newborn and family genetic screening programs
• Increased recognition of hereditary amyloid diseases
• Strong pipeline including CRISPR-based therapies and next-gen stabilizers
• Better access to specialty neuromuscular and cardiac centers
Segmentation Snapshot
By Treatment Type
• TTR Gene-Silencing Therapies (RNAi: Patisiran; ASOs: Inotersen)
• TTR Stabilizers (Tafamidis, Diflunisal)
• Liver Transplantation (Declining with new drug approvals)
• Supportive Neuropathy Management
• Emerging CRISPR & Gene Editing Therapies
By Disease Manifestation
• Neuropathy-Predominant (Polyneuropathy) - Largest Segment
• Mixed Neuropathy & Cardiomyopathy
• Autonomic Dysfunction
• Ocular & Renal Involvement
By Diagnostic Method
• Genetic Testing
• Nerve Conduction Studies (NCS/EMG)
• Tissue Biopsy
• MRI Neurography
• Serum Biomarkers & TTR Quantification
By End User
• Hospitals
• Neuromuscular Disorder Clinics
• Genetic Testing Centers
• Research Institutes
• Specialty Drug Distribution Networks
By Region
• North America (Largest Market)
• Europe
• Asia-Pacific (Fastest Growing)
• Latin America
• Middle East & Africa
Explore Full Report here: https://exactitudeconsultancy.com/reports/72015/familial-amyloid-polyneuropathy-market
Recent Developments
• Expansion of RNAi and ASO therapy approvals globally.
• Ongoing trials evaluating CRISPR-based TTR knockout therapies.
• Improved reimbursement frameworks for rare disease drugs.
• Partnerships between diagnostic labs and neurology centers to expand genetic screening.
Expert Quote - Irfan Tamboli, Business Development Executive
"RNA-based therapies have revolutionized treatment for hereditary amyloidosis. As gene-silencing and gene-editing solutions evolve, patient outcomes and disease management are reaching unprecedented levels."
Conclusion
The Familial Amyloid Polyneuropathy Market will continue expanding through 2034 as genetic screening improves, advanced RNA therapeutics gain adoption, and revolutionary gene-editing platforms move closer to approval. Companies investing in precision medicine, rare disease drug development, and global screening initiatives will drive the next era of innovation.
This report is also available in the following languages : Japanese (家族性アミロイドポリニューロパチー市場), Korean (가족성 아밀로이드 다발신경병증 시장), Chinese (家族性淀粉样多发性神经病市场), French (Marché de la polyneuropathie amyloïde familiale), German (Markt für familiäre Amyloidpolyneuropathie), and Italian (Mercato della polineuropatia amiloide familiare), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/request-sample/72015
Related Reports
Familial Lipoprotein Lipase Deficiency Market
https://exactitudeconsultancy.com/reports/72017/familial-lipoprotein-lipase-deficiency-market
Heterozygous Familial Hypercholesterolemia (HeFH) Market
https://exactitudeconsultancy.com/reports/72023/heterozygous-familial-hypercholesterolemia-hefh-market
Novel Hypercholesterolemia Drugs Market
https://exactitudeconsultancy.com/reports/73182/novel-hypercholesterolemia-drugs-market
Familial Hypercholesterolemia Market
https://exactitudeconsultancy.com/reports/71988/familial-hypercholesterolemia-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Familial Amyloid Polyneuropathy (FAP) Market to Reach USD 5.48 Billion by 2034 here
News-ID: 4304797 • Views: …
More Releases from Exactitude Consultancy
Flow Diverters Market Drives ,Trades 2034
Market Overview
The Flow Diverters Market is experiencing strong growth due to the rising prevalence of intracranial aneurysms and increasing adoption of minimally invasive neurovascular procedures. Flow diverters are specialized endovascular implants designed to redirect blood flow away from an aneurysm, promoting vessel healing and reducing rupture risk. These devices have significantly improved treatment outcomes for complex, wide-necked, and giant aneurysms that are difficult to treat with traditional coiling or clipping.
Advancements…
Cerebrospinal Fluid (CSF) Management Market Opportunities in 2034
Market Overview
The Cerebrospinal Fluid (CSF) Management Market is expanding steadily due to the increasing prevalence of hydrocephalus, traumatic brain injuries, intracranial hemorrhage, and neurodegenerative disorders that impair CSF circulation. CSF management devices are essential for maintaining normal intracranial pressure and preventing neurological damage in adult and pediatric patients.
Improved neurosurgical procedures, advancements in programmable shunt valves, and wider availability of external drainage systems are major contributors to market growth. Additionally, innovation…
Brain Implants Global Market Demand, Trades 2025-2034
Market Overview
The Brain Implants Market is witnessing strong growth driven by rising neurological disorders, increasing acceptance of neurostimulation therapies, and rapid technological advancements in implantable devices. Brain implants, also known as neural implants, are medical devices placed directly into the brain to restore neurological functions, support cognitive processes, or control motor functions in patients with chronic neurological conditions.
The market benefits from increasing demand for deep brain stimulation (DBS), spinal cord…
Endogenous Cushing's Syndrome Market to Reach USD 1.97 Billion by 2034
Pune, India - December 2025 - The global Endogenous Cushing's Syndrome Market, valued at USD 1.13 billion in 2024, is projected to reach USD 1.97 billion by 2034, growing at a 5.6% CAGR (2025-2034), according to Exactitude Consultancy. Rising awareness, improved endocrine diagnostics, and innovation in cortisol-lowering therapies are key market growth catalysts.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72013
Market Summary
The Endogenous Cushing's Syndrome Market is expanding as…
More Releases for Familial
Homozygous Familial Hypercholesterolemia Market Outlook 2024-2034
Introduction
Homozygous familial hypercholesterolemia (HoFH) is a rare, life-threatening genetic disorder characterized by extremely high cholesterol levels from birth. Patients with HoFH are at a very high risk of premature atherosclerotic cardiovascular disease (ASCVD), often developing complications as early as childhood. While the condition is rare-affecting approximately 1 in 160,000 to 300,000 individuals globally-it has become a major focus for pharmaceutical innovation due to the severity of the disease and the…
Familial Adenomatous Polyposis (FAP) Therapeutics- Pipeline Analysis 2018
Familial adenomatous polyposis (FAP) is a genetic disorder, characterized by the development of adenomatous colon polyps in the intestinal tract, resulting in colon cancer. The disease is diagnosed when more than 100 adenomatous colon polyps are developed in a person.
Download the sample report at: https://www.pharmaproff.com/request-sample/1025
A person with FAP is at a high risk of developing cancer of small intestines or stomach. This disease is categorized into three types including attenuated…
Heterozygous Familial Hypercholesterolemia (heFH) Therapeutics - Pipeline Analys …
Heterozygous familial hypercholesterolemia (HeFH) is an inherited genetic disorder that affects the body’s ability to control cholesterol. It is characterized by very high LDL (low density lipoprotein) cholesterol (above 190 for adults or above 160 for children) and family history of high cholesterol, heart disease or stroke.
Download the sample report @ https://www.pharmaproff.com/request-sample/1135
A very high level of LDL from birth leads to a twenty-fold increase in the risk of premature…
Familial Amyloid Cardiomyopathy Treatment Market Opportunity Analysis, 2018–20 …
Aggregation and deposition of mutant and wild-type transthyretin protein (TTR) in heart results in familial amyloid cardiomyopathy, which typically occur after age of 60. Familial amyloid cardiomyopathy is also known as hereditary cardiac transthyretin amyloidosis or hereditary amyloid cardiomyopathy. The protein transthyretin amyloid fibrils infiltrate the myocardium that leads to diastolic dysfunction from restrictive cardiomyopathy, which eventually result to heart failure. There are several mutation in TTR which are associated…
Familial Adenomatous Polyposis Pipeline Therapeutics Development Market Review 2 …
RnRMarketResearch.com adds “Familial Adenomatous Polyposis - Pipeline Review, H1 2017” to its store providing an overview of the Familial Adenomatous Polyposis therapeutic pipeline with comprehensive information on the therapeutic development for Familial Adenomatous Polyposis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews…
Familial Adenomatous Polyposis - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Familial Adenomatous Polyposis - Pipeline Review, H1 2017 to its growing collection of premium market research reports.
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Familial Adenomatous Polyposis - Pipeline Review, H1 2017, provides an overview of the Familial Adenomatous Polyposis (Genetic Disorders) pipeline landscape.
Familial adenomatous polyposis (FAP) is also known as familial polyposis coli, adenomatous polyposis coli, or…
